U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal…
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate PF-06928316 or RSVpreF for!-->…